Gregg Sherman, MD
National Association for Continuing Education
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Joshua Kilbridge, President
San Francisco, CA
Heart failure (HF) is a growing problem in the United States, affecting an estimated 5.1 million Americans ≥20 years of age. The disease is a cause for even greater concern among African Americans, in whom the relative incidence is 50% higher compared with the general population. Despite the availability of various treatment options, HF care is suboptimal in clinical practice. Provider barriers include knowledge barriers, diagnostic challenges, pharmacological concerns, communication issues, and personal factors. Early detection of HF can improve outcomes, but the symptoms and signs of HF are often difficult to identify because they are frequently confused with other disorders or are attributed to aging, obesity, or lack of conditioning. As a result, HF is misdiagnosed or underdiagnosed. HF patients may not receive any intervention or may be undertreated, resulting in a very small number of patients reaching goals and recommended levels of therapy with standard treatments including beta blockers, ACE inhibitors, ARBs, and diuretics.
After many years, new treatment options are available with novel mechanisms of action that can improve outcomes when added to optimized, guideline directed medical therapy. This program will raise awareness of risk factors for heart failure including African Americans and other ethnic minorities, discuss the role of biomarkers, help participants understand the indications for new therapies, and demonstrate how to appropriately incorporate them into clinical practice.
This activity utilizes a flipped classroom design. This begins with a foundational self-study followed by an online live webinar, which will be available on-demand after the live event, where all participants will have the opportunity to interact with the faculty and other learners.
DISCLOSURE POLICY STATEMENT:
It is the policy of ABC and NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While ABC and NACE endeavor to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Barbara Hutchinson, MD, PhD, FACC has no real or apparent conflicts of interest to report.
Anekwe Onwuanyi, MD serves as a speaker for Novartis.
Gregg Sherman, MD has no real or apparent conflicts of interest to report.
Harvey Parker, PhD has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
ABC and NACE require that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of ABC and NACE. The information is presented for the purpose of advancing the attendees' professional development.
The Association of Black Cardiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
CREDIT DESIGNATION STATEMENT:
The Association of Black Cardiologists designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education approves this program for 1.0 hr contact hours of continuing education (which includes 0.25 hours of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
This activity is provided by The Association of Black Cardiologists and The National Association for Continuing Education.
This activity is supported by educational funding provided by Novartis Pharmaceuticals.
Copyright © 2016 Association of Black Cardiologists and National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of ABC and NACE is prohibited.